TIDMABDX
Abingdon Health PLC
12 May 2022
Abingdon Health plc
("Abingdon" or "the Company")
Strategic collaboration with Bimelix Ab
Focused on the on development and commercialisation of Lyme
disease lateral flow self-test
York, U.K. 12 May 2022: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality
and effective rapid tests, and Bimelix Ab ("Bimelix"), a
Finnish-based accredited biomedical laboratory providing services
including clinical and research-based diagnostics as well as the
development of new testing methods, announce a strategic
collaboration to develop, manufacture and commercialise a Lyme
disease lateral flow self-test ("LFT").
Abingdon and Bimelix have been collaborating for over 12 months
on the feasibility of developing a Lyme disease LFT self-test.
Under the terms of the agreement, Abingdon and Bimelix will jointly
complete the development of the Lyme disease test and scale-up to
manufacture, and will also be jointly responsible for the
commercialisation of the test.
Lyme disease, also known as Lyme borreliosis, caused by
spirochetes belonging to the Borrelia burgdorferi sensu lato
complex, is the most common tick-borne infection in Europe.
Currently, laboratory diagnosis of Lyme disease is mainly based on
the patient's medical history, clinical signs and symptoms, in
combination with the detection of Borrelia-specific antibodies,
where indirect enzyme-linked-immunosorbent assay (ELISA) is the
most widely used technique. Typical symptoms include fever,
headache, fatigue, and a characteristic skin rash called erythema
migraines. This rash occurs in approximately 60-80% of infected
persons and begins at the site of a tick bite after a delay of 3-30
days. A distinctive feature of the rash is that it gradually
expands peripherally over a period of several days. If left
untreated, infection can spread to joints, the heart, and the
nervous system. Most cases of Lyme disease can be treated
successfully with a course of antibiotics.
The global risk of Lyme disease is expected to increase in the
coming years as tick habitats expand in response to environmental
factors and climate change. Therefore, there is a large unmet need
for a fast, effective Lyme disease self-test to enable quicker
diagnosis and treatment.
Chris Yates, Chief Executive Officer of Abingdon Health,
commented:
"We are delighted to partner with Bimelix, a company at the
forefront of research into the rapid diagnosis of Lyme disease.
Undiagnosed Lyme disease can spread to other parts of your body for
several months to years after infection, causing arthritis and
nervous system problems. The early diagnosis and rapid treatment of
Lyme disease will reduce these additional complications and improve
patient outcomes."
Mathias Grunér, Chief Executive Officer of Bimelix,
commented:
"To be able to partner with Abingdon Health, a leading company
in development of rapid test systems, gives us an ideal opportunity
to make years of research on Lyme disease diagnostics broadly
available in a rapid test system of the highest quality. This will
make early diagnosis of Lyme disease accessible globally and will
be of great value to both patients and healthcare
professionals."
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross, Chief Financial Officer
Dr Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Shaun Dobson, Peter Steel, Alex Bond (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Mob: +44 (0)7980 541 893 / +44 (0)7867 984
Marriage 082
Alice Woodings Mob: +44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a world leading developer and manufacturer of
high-quality rapid tests across all industry sectors, including
healthcare and COVID-19. Abingdon is the partner of choice for a
growing global customer base and takes projects from initial
concept through to routine and large-scale manufacturing and has
also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
About Bimelix Ab
Bimelix is a Finnish-based accredited biomedical laboratory
providing services including clinical and research-based
diagnostics as well as the development of new testing methods.
Bimelix is also offering laboratory analyses for research projects
and collaborations and has been actively working on the diagnosis
of Lyme disease for the past 10 years and has been involved in the
publication of a number of research reports highlighting the
incidence and prevalence of Lyme disease in Scandinavia (D Nyman, M
Nordberg, S Olausson, S-A Carlsson: Serologic risk-stratification
of borreliosis by a novel borrelia C6-peptide IgG1subclass antibody
test, International Symposium on Tick-Borne Pathogens and Disease
ITPD, Wien, Sept, 08-11, 2019).
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUQAAUPPGQG
(END) Dow Jones Newswires
May 12, 2022 02:02 ET (06:02 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2023 to Mar 2024